Soligenix (SNGX) Competitors

Soligenix (NASDAQ:SNGX) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.

Do analysts recommend SNGX or DARE?

Daré Bioscience has a consensus price target of $12.00, indicating a potential upside of 312.37%. Given Daré Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Daré Bioscience is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Daré Bioscience	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer SNGX or DARE?

In the previous week, Daré Bioscience had 2 more articles in the media than Soligenix. MarketBeat recorded 6 mentions for Daré Bioscience and 4 mentions for Soligenix. Daré Bioscience's average media sentiment score of 0.54 beat Soligenix's score of -0.60 indicating that Daré Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Daré Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, SNGX or DARE?

Soligenix has higher earnings, but lower revenue than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	-$117.03K	-52.57	-$6.14M	-$4.29	-0.44
Daré Bioscience	$9.78K	2,632.21	-$30.16M	-$0.17	-17.12

Which has more volatility and risk, SNGX or DARE?

Soligenix has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Is SNGX or DARE more profitable?

Daré Bioscience has a net margin of -191.65% compared to Soligenix's net margin of -1,473.38%. Daré Bioscience's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	-1,473.38%	-223.29%	-74.18%
Daré Bioscience	-191.65%	N/A	-18.98%

Do insiders and institutionals hold more shares of SNGX or DARE?

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 4.0% of Daré Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in SNGX or DARE?

Daré Bioscience received 80 more outperform votes than Soligenix when rated by MarketBeat users. Likewise, 73.36% of users gave Daré Bioscience an outperform vote while only 72.97% of users gave Soligenix an outperform vote.

Company	Underperform	Outperform
Soligenix	Outperform Votes 278 72.97%	Underperform Votes 103 27.03%
Daré Bioscience	Outperform Votes 358 73.36%	Underperform Votes 130 26.64%

Summary

Daré Bioscience beats Soligenix on 15 of the 18 factors compared between the two stocks.